AstraZeneca-Alexion merger slides through FTC review after supposed M&A crackdown poses no barriers
The AstraZeneca-Alexion megamerger received a good sign Friday, despite warning signs of the tides turning against large M&A pharma deals.
US regulators at the FTC have cleared the acquisition for approval, AstraZeneca announced, all but signing off on the deal to go through once it officially closes in the third quarter. AstraZeneca originally said it was planning to buy out Alexion back in December for $39 billion.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 118,000+ biopharma pros reading Endpoints daily — and it's free.